Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. Involving more than 250 investigators based at 19 hospital sites across the UK, the study has analysed genetic signatures in lung tumours, tracking how they have evolved over the past nine years in more than 815 patients.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.

Vaccine 40

Vaccine Research Doctors Laboratories 40

The Pharma Data

SEPTEMBER 18, 2020

This week Pharma IQ looks at how the pharma industry is expanding its vaccine manufacturing and testing protocols to ensure the deadly Covid-19 outbreak yields in its spread around the globe. . BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October.

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. This is the focus of vaccines in development and convalescent plasma therapy. The test targets antibodies against the spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. BARCELONA, Spain , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

The Pharma Data

MARCH 8, 2022

Dr. Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice. Camouflage protects virus from immune system. Researchers led by Prof.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. Given the numbers involved, these persistent symptoms likely represent great future challenges for healthcare systems.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Ricks , Lilly chairman and CEO.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

PerkinElmer

FEBRUARY 28, 2022

Fast-forward to today, and thousands of scientists have turned their attention to studying SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. This research pivot led to a torrent of scientific papers describing the structure and biology of the virus being published. μl of ATPlite-substrate per well.

Virus 52

Virus Vaccine Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 17, 2020

17, 2020 (American Heart Association News) — People with obesity – regardless of age – are more likely to be hospitalized with COVID-19 and have higher risks for complications and death, according to new research. It was already known that obesity can worsen the outcomes from COVID-19, increasing the risk of hospitalizations and death.

Hospitals 52

Hospitals Vaccine Virus Disease 52

Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . The company said: “As of the 28 September 2022, patients have been dosed with Auceliciclib, and dosing has completed for Cohorts 1 – 5 of the monotherapy dose escalation, and Cohorts 1a, 1b for the combination therapy arms with Temozolomide (TMZ). million from the Medical Research Future Fund.

Drugs 130

Drugs Science Therapies Clinical Trials 130

Creative Biolabs

SEPTEMBER 6, 2022

Researchers at Cincinnati Children’s Hospital Medical Center published a research paper in Nature titled: Pregnancy enables antibody protection against intracellular infection. At the same time, these findings will have far-reaching implications for antibody therapy in other areas. Reference Erickson, J.J.,

Vaccine 52

Vaccine Virus Clinical Trials Disease 52

The Pharma Data

OCTOBER 19, 2020

The assay targets on coronavirus-specific nanobodies and tests affinity and efficacy to prevent the virus infection. . Testing Therapies, Antivirals and Vaccines. There has been some discussion of running challenge trials for COVID-19 vaccines. The race for a COVID-19 vaccine continues to heat up as case numbers rise.

Vaccine 52

Vaccine Virus FDA Clinical Trials 52

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Antiviral therapies are used to help control disease, but they are limited by toxicity and the emergence of viral resistance.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . One of the open questions about the various vaccines against COVID-19 has been how long the protection offered will last.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The NIH continues to support the development of some very innovative therapies to control SARS-CoV-2, the coronavirus that causes COVID-19. Though more study is needed, the researchers say the decoy therapy could potentially be delivered directly to the lungs through an inhaler and used alone or in combination with other COVID-19 treatments.

Virus 52

Virus Clinical Trials Engineering Immune Response 52

The Pharma Data

JANUARY 25, 2021

With a mandate to serve patients and an emphasis on public health, CSL Behring is a co-founder of the CoVIg-19 Plasma Alliance , which aims to develop an anti-coronavirus hyperimmune globulin (H-Ig) made from a convalescent plasma for the treatment of hospitalized adults at risk for serious complications of COVID-19. “It

Vaccine 52

Vaccine Therapies Virus Trials 52

The Pharma Data

MARCH 22, 2022

During the pandemic, Pfizer will offer its oral therapy through a tiered pricing approach, pending country authorization or approval, based on the income level of each country to promote equity of access across the globe. High and upper-middle income countries will pay more than lower income countries.

Treatment 52

Treatment Virus Hospitals Therapies 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. “Tackling the COVID-19 pandemic will require a combination of public health measures, vaccines and therapeutics.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

JANUARY 6, 2021

. “In our cases, we think that tumors arose from mother-to-infant vaginal transmission through aspiration of tumor-contaminated vaginal fluids during birth,” said lead researcher Dr. Ayumu Arakawa, a pediatric oncologist with the National Cancer Center Hospital in Tokyo. The findings were reported Jan.

Vaccine 52

Vaccine Doctors Hospitals Virus 52

The Pharma Data

MAY 4, 2021

An initial donation of 400,000 baricitinib tablets is being made immediately available to the Indian government for eligible hospitalized COVID-19 patients in India and Lilly will work urgently to increase the quantity of donated product multifold over the coming weeks. Ricks , Lilly chairman and CEO.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Codon

MAY 11, 2023

3/ A Vaccine for RSV A vaccine called Arexvy, and marketed by GlaxoSmithKline, has been approved by the FDA for adults aged 60 and older. It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. The vaccine was 82.6 The vaccine was 82.6

Vaccine 52

Vaccine Engineering Licensing Licensing 52

Codon

MAY 11, 2023

3/ A Vaccine for RSV A vaccine called Arexvy, and marketed by GlaxoSmithKline, has been approved by the FDA for adults aged 60 and older. It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. The vaccine was 82.6 The vaccine was 82.6

Vaccine 52

Vaccine Engineering Licensing Licensing 52

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Due to the rapidly evolving and geographically diverse nature of the SARS-CoV-2 virus, continued scientific innovation remains critical to develop additional treatments. In the U.S.,

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Bamlanivimab and etesevimab together and bamlanivimab alone are not authorized for use in patients: who are hospitalized due to COVID-19, OR. who require oxygen therapy due to COVID-19, OR. Limitations of Authorized Use.

Government 52

Government Long-Term Care Facilities Hospitals Treatment 52

Agency IQ

NOVEMBER 3, 2023

regulatory landscape for probiotics and other microbiome-based therapies Probiotics, a type of microbiome-based therapy containing live micro-organisms, are broadly available on drug store and grocery store shelves, but the regulatory classifications for products containing the same micro-organism can differ dramatically. What’s next?

Therapies 40

Therapies Science FDA Production 40

Drug Discovery World

SEPTEMBER 16, 2022

Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. .

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

MARCH 24, 2021

Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus. Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. Overall R&D investment up 7% to 3.7 of net sales).

Vaccine 52

Vaccine Small Molecule Disease Therapies 52

The Pharma Data

OCTOBER 27, 2020

Fennell, FRCP , PhD : Professor Fennell is Professor & consultant in Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Program based at the University of Leicester/University Hospitals of Leicester NHS Trust. OSLO, Norway , Oct. Fennel cover the key scientific focus areas of Targovax. Dean A.

Virus 52

Virus Engineering Clinical Development International 52

The Pharma Data

JANUARY 19, 2021

We believe that Tempol could play a pivotal role not only in the treatment of COVID-19, but actually in preventing hospitalization. With new mutations occurring in the virus, it is apparent there is an ongoing need for new therapies. About Adamis Pharmaceuticals. The company’s subsidiary, U.S. Compounding, Inc.,

FDA 52

FDA Treatment Pharmaceuticals Government 52

The Pharma Data

OCTOBER 26, 2020

Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I Non-GAAP EPS of $1.74 Year-to-date results can be found in the attached tables.

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

JUNE 26, 2021

“Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalisations from severe forms of the disease,” said Levi Garraway, M.D., Roche has existing distribution channels established to ship Actemra/RoActemra to hospitals across the United States.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

JULY 23, 2021

Ronapreve is a combination of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19. We also continue to identify, develop and support potential therapies which can play a role in treating the disease.

Treatment 52

Treatment Virus Clinical Trials Government 52

The Pharma Data

MARCH 22, 2021

New infections continue to rise globally with over three million reported cases last week, so this investigational antibody cocktail may offer hope as a potential new therapy to high-risk patients – particularly in light of recent evidence showing that casirivimab and imdevimab together retain activity against key emerging variants.

Virus 52

Virus Clinical Trials Trials FDA 52